Skip to main content

Vonvendi FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 2, 2022.

FDA Approved: Yes (First approved December 8, 2015)
Brand name: Vonvendi
Generic name: von willebrand factor (recombinant)
Dosage form: for Injection
Company: Baxalta Incorporated
Treatment for: von Willebrand Disease

Vonvendi (von Willebrand factor (recombinant)) is a recombinant von Willebrand factor for the treatment of von Willebrand disease(VWD).

  • Vonvendi is indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease(VWD) for:
    • On-demand treatment and control of bleeding episodes.
    • Perioperative management of bleeding.
    • Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy.
  • Vonvendi is administered via intravenous infusion.

Development timeline for Vonvendi

Jan 31, 2022Approval FDA Approves Prophylactic Treatment with Vonvendi [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
Apr 17, 2018Approval FDA Approves Vonvendi [von Willebrand factor (recombinant)] for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease
Dec  8, 2015Approval FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.